Abstract:Tolerogenic DCs (tolDCs) are being researched as a promising intervention strategy also in autoimmune diseases including type 1 diabetes (T1D). T1D is a T-cell-mediated, organ-specific disease with several well-defined and rather specific autoantigens, i.e., proinsulin, insulin, glutamic acid decarboxylase 65 (GAD65), that have been used in animal as well as human intervention trials in attempts to achieve a more efficient, specific immunotherapy. In this study, we have tested tolerogenic DCs for their effectiveness to prevent adoptive transfer of diabetes by diabetogenic splenocytes into non-obese diabetes (NOD)-severe combined immunodeficiency (NOD-SCID) recipients. While i.p. application of tolDCs prepared from bone marrow of prediabetic NOD mice by vitamin D2 and dexamethasone significantly reduced diabetes transfer into the NOD-SCID females, this effect was completely abolished when tolDCs were loaded with the mouse recombinant GAD65, but also with a control protein-ovalbumin (OVA). The effect was not dependent on the presence of serum in the tolDC culture. Similar results were observed in NOD mice. Removal of possible bystander antigen-presenting cells within the diabetogenic splenocytes by negative magnetic sorting of T cells did not alter this surprising effect. Tolerogenic DCs loaded with an immunodominant mouse GAD65 peptide also displayed diminished diabetes-preventive effect. Tolerogenic DCs were characterized by surface maturation markers (CD40, CD80, CD86, MHC II) and the lipopolysaccharide stability test. Data from alloreactive T cell proliferation and cytokine induction assays (IFN-γ) did not reveal the differences observed in the diabetes incidence. Migration of tolDCs, tolDCs-GAD65 and tolDCs-OVA to spleen, mesenteric- and pancreatic lymph nodes displayed similar, mucosal pattern with highest accumulation in pancreatic lymph nodes present up to 9 days after the i.p. Application: These data document that mechanisms by which tolDCs operate in vivo require much better understanding for improving efficacy of this promising cell therapy, especially in the presence of an antigen, e.g., GAD65.

Involvement of Suppressive B-Lymphocytes in the Mechanism of Tolerogenic Dendritic Cell Reversal of Type 1 Diabetes in NOD Mice

Essential Roles Of Tgf-Beta In Anti-Cd3 Antibody Therapy: Reversal Of Diabetes In Nonobese Diabetic Mice Independent Of Foxp3(+) Cd4(+) Regulatory T Cells

Foxp3-expressing CD4+T Cells under the Control of IFN-γ Promoter Prevent Diabetes in NOD Mice

GAD-IgG-inducing CD4+Foxp3+Treg Cells Suppressing Diabetes Are Involved in the Increasing Ratio of CD80+:CD86+ Cells in NOD Mice

Natural Killer Cells Modulate Overt Autoimmunity to Homeostasis in Nonobese Diabetic Mice after Anti-CD3 F(ab′)2 Antibody Treatment through Secreting Transforming Growth Factor-β

Diabetes is Not Prevented by Foxp3-Transduced Cd4(+)T Cells under the Il-12r Beta 2 Promoter Control

Interleukin‐17‐producing Γδ+ T Cells Protect NOD Mice from Type 1 Diabetes Through a Mechanism Involving Transforming Growth Factor‐β

Tolerogenic Vaccination Reduced Effector Memory Cd4 T Cells and Induced Effector Memory Treg Cells for Type I Diabetes Treatment

Diabetes is Not Prevented by Foxp3-transduced CD4+T Cells under the IL-12Rβ2 Promoter Control

Tolerogenic dendritic cells pulsed with islet antigen induce long-term reduction in T-cell autoreactivity in type 1 diabetes patients

T Regulatory Cells to Prevent Autoimmune Diabetes and Promote Islet Allograft Survival in NOD Mice

Induction of Active Tolerance and Involvement of Cd1d-Restricted Natural Killer T Cells in Anti-Cd3 F(Ab ')(2) Treatment-Reversed New-Onset Diabetes in Nonobese Diabetic Mice

Interleukin-10+ regulatory B cells arise within antigen-experienced CD40+ B cells to maintain tolerance to islet autoantigens

Antigen Loading (e.g., Glutamic Acid Decarboxylase 65) of Tolerogenic DCs (tolDCs) Reduces Their Capacity to Prevent Diabetes in the Non-Obese Diabetes (NOD)-Severe Combined Immunodeficiency Model of Adoptive Cotransfer of Diabetes As Well As in NOD Mice

Intestinal Type 1 Regulatory T Cells Migrate to Periphery to Suppress Diabetogenic T Cells and Prevent Diabetes Development

TLR9-deficiency in B Cells Promotes Immune Tolerance Via IL-10 in a Type 1 Diabetes Mouse Model

B Lymphocytes Expressing High Levels of PD-L1 Are Key Regulators of Diabetes Development in Non-Obese Diabetic Mice.

Dynamic Number and Function of IL-10–Producing Regulatory B Cells in the Immune Microenvironment at Distinct Stages of Type 1 Diabetes

Lipopolysaccharide-Activated B Cells Down-Regulate Th1 Immunity and Prevent Autoimmune Diabetes in Nonobese Diabetic Mice1

Anti-CD20 Therapy Ameliorates Β Cell Function and Rebalances Th17/Treg Cells in NOD Mice

Regulatory CD4+ T cells redirected against pathogenic CD8+ T cells protect NOD mice from development of autoimmune diabetes